SCHEMBL24823966

SCHEMBL24823966

NCCCCNCc1nc2ncccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.45
CYP2C9 P11712 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
DRD4 P21917 1/20 0.39
METAP2 P50579 1/20 0.38
METAP1 P53582 1/20 0.38
SLC40A1 Q9NP59 4/20 0.38
PDE5A O76074 1/20 0.38
MC1R Q01726 1/20 0.38
HPSE Q9Y251 1/20 0.38
TP53 P04637 2/20 0.37
SLC2A1 P11166 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
BACE1 P56817 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719992 0.80 NUDT1 (0.53) NUDT1CYP2C9NOS1NOS2DRD4
SCHEMBL19012922 0.79 PKM (0.55) SLC40A1RAB9AHSD17B10
SCHEMBL13970740 0.79 NUDT1 (0.47) NUDT1CYP2C9NOS1NOS2DRD4
SCHEMBL4773954 0.76 NUDT1 (0.59) NUDT1CYP2C9NOS1NOS2DRD4
SCHEMBL6948805 0.75 PKM (0.57) NUDT1CYP2C9NOS1NOS2DRD4
SCHEMBL18661287 0.74 CHRM2 (0.51) DRD4SLC40A1HPSETP53ALDH1A1
SCHEMBL11360890 0.74 PKM (0.56) SLC40A1MC1RRAB9AHSD17B10
SCHEMBL21101319 0.74 CXCR4 (0.48) NUDT1CYP2C9NOS1NOS2DRD4
SCHEMBL5385517 0.73 NUDT1 (0.49) NUDT1METAP2METAP1PDE5ATP53
SCHEMBL4718043 0.73 CYP2C9 (0.45) NUDT1CYP2C9NOS1NOS2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409589-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY GENZYME CORP (US) 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409589-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY CCR5, CXCR4, CXCR3 NUDT1 1600/4885CYP2C9 3083/4885NOS1 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.